About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETED

Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias

NCT05969002•National Cancer Institute (NCI)

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

B CellAcute Lymphoblastic LeukemiaRelapsed/Refractory

Locations

1

United States

Locations (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Key Dates

Start Date

August 25, 2023

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

April 20, 2026

Related Studies

RECRUITINGEARLY Phase 1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT06735690

Acute Lymphoblastic Leukemia

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

NCT06074666

Acute Lymphoblastic Leukemia, Pediatric

RECRUITINGPhase 1

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

NCT04972942

T-cell Acute Lymphoblastic LeukemiaT-Cell Acute Lymphoblastic Lymphoma

RECRUITINGPhase 1/2

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539

Relapsed/Refractory Non-Hodgkin Lymphoma

RECRUITINGPhase 1

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT07260812

Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma (DLBCL)

RECRUITINGPhase 3

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286

Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

View all related studies

Sponsors

Lead Sponsor

National Cancer Institute (NCI)

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 20, 2026Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions